(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 September 2008 (04.09.2008)

PCT

(10) International Publication Number
WO 2008/104523 A1

(51) International Patent Classification:
G01N 33/574 (2006.01)

(21) International Application Number:
PCT/EP2008/052271

(22) International Filing Date:
25 February 2008 (25.02.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07103094.4 27 February 2007 (27.02.2007) EP

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **GRAUS PORTA, Diana** [ES/CH]; Sevogelstrasse 34, CH-4052 Basel (CH). **GUAGNANO, Vito** [IT/CH]; Thannerstrasse 66, CH-4054 Basel (CH). **GARCIA-ECHEVERRIA, Carlos** [ES/CH]; Engelgasse 126, CH-4052 Basel (CH).

(74) Agent: **DYER, James**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report*

(54) **Title:** A METHOD OF IDENTIFICATION OF CELLS THAT SHOW SENSITIVITY TO MODULATION OF SIGNALING MEDIATED BY A FIBROBLAST GROWTH FACTOR RECEPTOR OR A VARIANT THEREOF

Fig. 1



(57) **Abstract:** The invention is based on the finding that cells that show (especially tyrosine) phosphorylation of FGF-R substrate 2 (FRS-2), in contrast to cells that lack such phosphorylation, allow a prediction that treatment with a modulator, especially an inhibitor, of Fibroblast Growth Factor-Receptor signaling will be successful in cells e.g. from biological samples from patients that show such phosphorylation. Therefore, the phosphorylation of FRS-2 can serve as a biomarker for the possibility of successful treatment. The invention relates to various methods, uses, kits and reagents useful in applying this biomarker.

WO 2008/104523 A1